News
Press ReleaseRevive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units
TORONTO, Feb. 05, 2020 - Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the...
Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
TORONTO, Jan. 20, 2020 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s...
Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases
TORONTO, Jan. 06, 2020 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical...
Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives
TORONTO, Dec. 19, 2019 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to provide an update on its...
Revive Therapeutics Announces New Leadership Appointment and Board Change
TORONTO, Dec. 18, 2019 - Revive Therapeutics Ltd. (“Revive" and the “Company") (CSE: RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions...
Revive Therapeutics Announces Results for the Three Months Ended September 30, 2019
TORONTO, Nov. 27, 2019 - Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, today announced its results for the...